
12-15-04



The Joseph

PTO/SB/30 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Request for Continued Examination (RCE) **Transmittal**

Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

| 30 (0 30k3 14 14 0 30 30t(0 0 11 3 | MOTO CHICAGO IL GOTTAGINO DI TAMO |
|---|-----------------------------------|
| Application Number | 09/902,176 |
| Filing Date | July 10, 2001 |
| First Named Inventor | Stefan Schreiber |
| Art Unit | 1634 |
| Examiner Name | Sally A. Sakelaris |
| Attorney Docket Number | 25481-P001X1 |

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8,

| 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2. | | | | | | |
|---|---|-----------------------|------------------------|------------------|--|--|
| 1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). | | | | | | |
| a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. | | | | | | |
| i | Consider the arguments in the Appeal Brief or Reply Brief previously filed on | | | | | |
| li. | Other | | | | | |
| b. 🗹 En | nclosed | | | | | |
| 1. ✓ | Amendment/Reply | iii. 🗸 Info | rmation Disclosure St | tatement (IDS) | | |
| ii. 🗸 | Affidavit(s)/ Declaration(s) | iv. Oth | er | | | |
| 2. Miscellaneous | | | | | | |
| | uspension of action on the above-identified applicat | tion is requested und | der 37 CFR 1.103(c) 1 | for a | | |
| a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) | | | | | | |
| b. Other | | | | | | |
| 3. Fees T | he RCE fee under 37 CFR 1.17(e) is required by 37 | CFR 1.114 when the | he RCE is filed. | | | |
| | he Director is hereby authorized to charge the follow | | | | | |
| a. 🔲 D | eposit Account No. | . I have enclosed a | duplicate copy of this | s sheet. | | |
| i. 🔽 | RCE fee required under 37 CFR 1.17(e) 12/16/2004 AWONDAF1 00000080 09902176 | | | | | |
| ii. √ | Extension of time fee (37 CFR 1.136 and 1.17) | 01 FC:2 | 2801 | 395.00 OP | | |
| iii. | Other | | | | | |
| b. √ C | Check in the amount of \$ \$395; \$510enclosed | | | | | |
| c. Payment by credit card (Form PTO-2038 enclosed) | | | | | | |
| WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | | | |
| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED | | | | | | |
| Signature | Milissa D. Schwaller | , , OKILT, OKINGE | Date | December 14,2004 | | |
| Name (Print/Type) | Melissa D. Schwaller | ! | Registration No. | 46,089 | | |
| CERTIFICATE OF MAILING OR TRANSMISSION | | | | | | |
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below. | | | | | | |
| Signature | | ı | | | | |
| Name (Print/Type) | | | Date | | | |

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Stefan Schreiber et al.

Serial No.:

09/902,176

Filed:

July 10, 2001

Title:

DIAGNOSTIC USE OF POLYMORPHISMS IN THE GENE CODING FOR THE TNF

RECEPTOR II AND METHODS FOR DETECTING NON-RESPONDERS TO

ANTI-TNF THERAPY

Confirm No.: 7507

Art Unit:

1634

Examiner:

Sally A. Sakelaris

Mail Stop: RCE

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sirs:

AMENDMENT AND RESPONSE TO OFFICE ACTION ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION (RCE) UNDER 37 C.F.R. § 1.114

Concurrent with this Amendment, Applicant has filed a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 in the present Application. This Request is in response to the Final Official Action mailed on June 14, 2004 (with a three-month shortened period for response set to expire on September 14, 2004) and the Examiner Interview held October 26, 2004. As said period has expired, accompanying this Request is a petition, under 37

> Express Mail Label No. EV 507 272 571 US

ATTORNEY DOCKET NO 25481-P001US

C.F.R. § 1.136, for a three-month extension of time and the necessary fee, as set forth in 37 C.F.R. § 1.17(a).

Please amend the above-identified Application as follows:

Amendments to the Claims are reflected in the listing of claims, which begin on Page 3 of this paper.

Remarks/Arguments begin on Page 4 of this paper.